NYSE : SNN

Smith & Nephew plc — News

$30.11 USD

$0.42 (1.41%)

Volume
1.44M
Average Volume
1.79M
Market Capitalization
$12.64B
P/E Ratio
19.76
Dividend Yield
2.61%
Price Target
$30.93
Year High
$38.79
Year Low
$28.56
Day High
Day Low
Payout Ratio
$0.52
Current Ratio
$2.14
Source Headline
Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week

Canton, Ohio—As thousands of football fans descend on Canton for the 2026 Pro Football Hall of Fame Enshrinement Week, Smith+Nephew, the Global medical technology company, will join the celebration with a series of engagement activities highlighting the connection between movement, recovery and the enduring spirit of the game. Smith+Nephew is the official Joint Replacement and Sports Medicine Technology Partner of the Pro Football Hall of Fame.

globenewswire.com - 2026-08-05 13:00:00

Smith & Nephew plc (SNN) Q2 2026 Earnings Call Transcript

Smith & Nephew plc (SNN) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-08-04 15:00:01

Smith & Nephew cuts sales outlook after weak US trading

Smith & Nephew PLC (LSE:SN) has cut its full-year revenue growth forecast after weakness in its US orthopaedics and wound care businesses in the second quarter. The FTSE 100 medical technology group now expects annual revenue growth of around 4%, down from its previous forecast of around 6%.

proactiveinvestors.co.uk - 2026-08-04 03:09:12

Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Smith and Nephew SNATS, Inc. (NYSE: SNN - Get Free Report) have received a consensus rating of "Hold" from the six brokerages that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month

defenseworld.net - 2026-08-03 04:16:04

Smith+Nephew Expands ASC Platform to Support Value-Based Care

SNN expands ASC Solutions with an integrated platform, analytics and partners to boost efficiency, growth and patient outcomes in outpatient care.

zacks.com - 2026-07-23 14:30:37

Smith+Nephew Launches LYNX COBLATION Wand for ENT Airway Surgery

SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.

zacks.com - 2026-07-16 12:46:08

New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised journal of surgery Die Chirurgie. The new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.

globenewswire.com - 2026-07-09 02:00:00

New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany. Published in internationally recognised journal of surgery Die Chirurgie, the new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.

globenewswire.com - 2026-07-09 02:00:00

Smith & Nephew: Ongoing Business Progress And A More Attractive Price

Smith & Nephew continues to demonstrate solid business recovery, with robust revenue, profit, and free cash flow growth across all divisions. SNN's 2026 outlook targets 6% underlying revenue growth, 8% organic trading profit growth, and $800 million in free cash flow, with a new $500 million share buyback announced. Completion of the 12-point plan delivered mixed results: revenue growth targets were met, but trading margin fell short, prompting a new 'RISE' strategy with 2028 financial targets.

seekingalpha.com - 2026-06-25 07:28:56

Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript

Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript

seekingalpha.com - 2026-06-11 09:12:10

Smith & Nephew's robotics push wins surgeon backing

Smith & Nephew PLC (LSE:SN) efforts to expand its surgical robotics platform and strengthen its orthopaedics pipeline received a vote of confidence from surgeons at a recent investor event, according to analysts at JPMorgan. Analyst Veronika Dubajova said discussions at the medical technology group's Expert Surgeon Insights event in London left her incrementally more positive on the prospects for CORI, Smith & Nephew's robotic-assisted surgery platform.

proactiveinvestors.co.uk - 2026-06-10 11:30:55

Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings.

globenewswire.com - 2026-06-08 13:23:00

Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.1-3

globenewswire.com - 2026-06-01 15:00:00

VEEV Boosts MedTech Quality Management With Smith+Nephew Partnership

Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.

zacks.com - 2026-05-13 13:25:39

Get SNN Insider Trade Alerts

SNN Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$30.93

2 analysts

Last Year

$33.47

5 analysts

All Time

$32.39

6 analysts

SNN Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-08-06 JP Morgan Downgrade Overweight Neutral
2026-08-05 Barclays Downgrade Equal Weight Underweight
2026-05-11 Canaccord Genuity Maintain Hold Hold
2026-03-05 Canaccord Genuity Maintain Hold Hold